Evaluation of Serum Neutrophil Gelatinase Associated Lipocalin Level as an Early Biomarkers for Type 2 Diabetic Nephropathy

Abstract

Background: Diabetic nephropathy is an emerging clinical and public health challenge and is related with adverse outcomes including ESRD and heart failure, as well as kidney replacement therapy , deaths related to these terminal illnesses . Diabetic kidney disease DKD and CVD are leading causes of morbidity and mortality in T2DM. The Neutrophil Gelatinase Associated Lipocalin (NGAL) is specifically released into blood and urine as a reaction to nephron injury. Higher levels of NGAL were reported in patients with diabetes in comparison to healthy nondiabetic individuals.
The aim of study: The study aims to evaluate the The study aims to evaluate the serum NGAL as biomarker for early detection of nephropathy in type 2 diabetic patients.Patients & Methods: Case control study was carried out in Salah-Addin city in private nephrologist clinic from 1t October 2020 to 1st February 2021.The study included conducted on 90 individuals , 60 diagnosed T2DM patients ( 30 had diabetic nephropathy which had albuminurea and 30 had diabetic without nephropathy had normal urine albumin) and the remaining 30 who participated as a control group. Blood samples were collected from each patients and controls to evaluate the levels of NGAL. All data were analyzed by a computer using SPSS program.Results:The study showed significant difference in serum NGAL (mean±SE) (1131.00±84.88 pg\ml ) . The Pearson correlation test showed that there was non significant negative Correlation of serum NGAL with age and with serum creatinine.Conclusions: The results of the current study showed a significant increase in serum NGAL level of DN patients with T2DM and may be considers a good biomarker for prediction in the case of diabetic nephropathy.